None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patient with Established type 2 diabetes (duration 1-10 years), on oral hypoglycemic agents (like Metformin or Glibenclamide) willing to participate in the study; Between 18-60 years.
Exclusion criteria
Exclusion criteria: Patient on insulin or patients with diabetic complications like neuropathy, retinopathy, nephropathy, diabetic foot, chronic ulcer and cardiovascular diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fold expression level of genes related to endocrine, metabolism, Insulin signalling and regulation. Specific genes involved in the enzymatic degradation of insulin including PplGl.3, TC69229, UPlQ93YG9 and PPARG, KCNJ11, CDKAL1, CDKN2A-CDKN2B, IDE-KIF11-HHEX, IGF2BP2 SLC30A8 and other associated gene involved in the progression and onset of type 2 diabetes. Timepoint: | — |
Secondary
| Measure | Time frame |
|---|---|
| Significant changes in the Expression level Insulin-degrading enzyme. Significant effect of practicing Pranayama for the management of type 2 diabetes mellitus. AEs observed and reported by the patient, after practicing seven sequence of Pranayama.Timepoint: | — |
Countries
India